A lecture on the pathogenesis and treatment of cardiorenal syndrome, which is a combination of various variants of renal and heart failure, is presented in the article. Currently, there are five types of this syndrome. All of them are discussed in detail from the view of relevance for urological practice. In patients of the urological profile, II type, to a lesser extent III and V types of cardiorenal syndrome are most common. Moreover, type II, which is the simultaneous coexistence of chronic heart failure and chronic renal failure due to different (unrelated causal relationships) conditions, can significantly influence on the choice of surgical tactics. This question requires further research. Type III of cardiorenal syndrome, which is a cardiac complication of a prolonged acute phase of acute renal failure, in most cases can be prevented through drug treatment and timely renal replacement therapy. Type V cardiorenal syndrome, which represents a combined damage to the heart and kidneys within the same condition, apparently, occurs in urological practice in the most severe patients with metabolic syndrome, which allows to combine uric acid stones and other variants of gouty nephropathy into one nosology, naturally leading to progressive renal failure, ischemic heart disease and chronic heart failure. In the section on treatment tactics, it is mentioned that there are no standard approaches to the treatment of cardiorenal syndrome in the literature. The restrictions in the choice and dosing regimen of cardiotropic drugs due to renal failure are considered in detail. The importance of timely hemodialysis is especially emphasized. In conclusion, the authors suggest that the development of cardiorenal syndrome is due to the effect of potentiation with a significantly higher rate of progression of both renal and heart failure compared to isolated forms of both conditions.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cardiorenal syndrome
24
heart failure
16
renal failure
16
treatment cardiorenal
8
syndrome
8
renal heart
8
failure
8
urological practice
8
chronic heart
8
renal
7

Similar Publications

Ascites syndrome (AS) is a deadly condition in fast-growing chickens, preceded by pulmonary arterial hypertension (PAH), where the angiotensin II type 1 receptor (ATR1) plays a role. We investigated whether allicin (ALLI), a garlic derivative, could (a) interact with broiler ATR1, (b) affect ascites-related traits [haematocrit content (Hct%), blood oxygen saturation (SaO), and the right-to-total ventricular weight ratio (RV:TV)], (c) modify ATR1 expression in the lung, heart, and liver, alongside ascites mortality and growth performance in Ross 308 broilers raised at high altitude and under cold temperatures promoting PAH/AS. Three groups (n = 70 each) were studied: 0-ALLI (untreated), 1-ALLI (allicin 1 mg/kg body weight/daily at 14-27 days of age by oral-oesophageal route), and 2.

View Article and Find Full Text PDF

Background: There is little research on cardiorenal anemia syndrome (CRAS) in China. This study was to describe the characteristics of patients with CRAS and to explore risk factors of all-cause death.

Methods: A total of 81,795 patients were hospitalized from August 2012 to August 2021 in the nephrology department and cardiology department, of which 820 patients with CRAS were recruited into this study.

View Article and Find Full Text PDF

Elevated triglyceride glucose index is associated with advanced cardiovascular kidney metabolic syndrome.

Sci Rep

December 2024

Department of Cardiology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.

The cardiovascular kidney metabolic (CKM) syndrome is a dynamic geriatric condition that has received limited research attention regarding its potential associations with the triglyceride glucose (TyG) index. This study aims to explore the potential association between the TyG index and advanced CKM syndrome. Data for this cross-sectional study were obtained from the National Health and Nutrition Examination Survey (NHANES) conducted between 2011 and 2018.

View Article and Find Full Text PDF
Article Synopsis
  • Dapagliflozin is a promising treatment for Acute Heart Failure (AHF), showing benefits in reducing cardiovascular mortality and hospital readmissions compared to traditional therapies.
  • A systematic review of five randomized controlled trials indicated that dapagliflozin significantly lowered in-hospital cardiovascular mortality rates and 30-day hospital readmissions without impacting hospital stay length or hypotension incidents.
  • The research followed established protocols for data extraction and quality assessment, demonstrating a notable weight change in patients receiving dapagliflozin, reinforcing its efficacy as a treatment option in AHF.
View Article and Find Full Text PDF

Acute heart failure is associated with high hospitalization and mortality rates. A strong, independent risk factor for mortality in patients with heart failure is acute kidney injury, and the condition caused by this connection between disturbances in heart function and proper kidney functioning is cardiorenal syndrome (CRS). This case report discusses the role of continuous renal replacement therapy (CRRT) in the management of a CRS case with septic shock due to pneumonia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!